BCM
BIO icon

BlueCrest Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

BlueCrest Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,465
Closed -$1.98M – 472
2019
Q1 		$1.98M Buy
+6,465
New +$1.74M 0.08% 179
2018
Q4 		– Sell
-2,633
Closed -$824K – 893
2018
Q3 		$824K Sell
2,633
-548
-17% -$170K 0.02% 525
2018
Q2 		$918K Sell
3,181
-71,526
-96% -$19.7M 0.02% 560
2018
Q1 		$18.7M Sell
74,707
-38,205
-34% -$9.73M 0.58% 24
2017
Q4 		$26.9M Buy
112,912
+40,347
+56% +$9.78M 0.73% 16
2017
Q3 		$16.1M Sell
72,565
-59,286
-45% -$13.3M 0.66% 27
2017
Q2 		$29.8M Sell
131,851
-56,021
-30% -$12.2M 1.16% 5
2017
Q1 		$37.5M Buy
187,872
+121,602
+183% +$23.4M 1.77% 2
2016
Q4 		$12.1M Buy
66,270
+64,427
+3,496% +$11M 0.66% 22
2016
Q3 		$302K Buy
+1,843
New +$280K 0.01% 614
2016
Q2 		– Sell
-9,190
Closed -$1.26M – 858
2016
Q1 		$1.26M Buy
+9,190
New +$1.21M 0.08% 332

Other funds holding BIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.31B AUM 18.17% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

BlueCrest Capital Management's BIO Position: Q2 2019 in Review

BlueCrest Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2019, closing a stake of 6,465 shares — an estimated $1.98M sold.

BlueCrest Capital Management first reported a position in BIO in Q1 2016 and held it in 11 quarters. The position peaked at $37.5M in Q1 2017. 330 funds tracked by Wall St. Rank hold BIO as of Q2 2019.

  • BlueCrest Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 6,465 Bio-Rad Laboratories Class A shares in Q2 2019, an estimated $1.98M.
  • BlueCrest Capital Management first reported a position in Bio-Rad Laboratories Class A in Q1 2016 and held it in 11 quarters.
  • BlueCrest Capital Management's Bio-Rad Laboratories Class A position peaked at $37.5M in Q1 2017.
  • 330 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2019.

Based on BlueCrest Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.